Fear of Cancer Recurrence
Conditions
Keywords
Fear of Cancer Recurrence, Emotional Freedom Techniques, Mindfulness Meditation, Cancer survivors, Psychosocial cancer-related symptoms
Brief summary
In this trial, the investigators introduce two internet-based psychological methods to meet the currently unmet medical need to cope with Fear of Cancer Recurrence (FCR) beyond the acute phase of cancer treatment: internet-based emotional freedom techniques (iEFT) and internet-based mindfulness intervention (iMMI). The primary aim of this trial is to examine the efficacy of Internet-Based Emotional Freedom Techniques (iEFT) and Internet-Based Mindfulness Meditation Intervention (iMMI) to alleviate Fear of Cancer Recurrence (FCR) in cancer survivors, as determined through the Fear of Cancer Recurrence Inventory (FCRI) in cancer survivors. To translate a statistically significant effect on FCR into a clinically significant change, the investigators would need to detect a between-group difference in mean FCRI at T1 of 10 points using an independent samples t-test (two experimental groups are compared against a single wait-list control). When the application of iEFT and/or iMMI appears effective to reduce FCR, these self-help methods could be implemented in clinical settings. The use of these low cost interventions with a low threshold, by an internet-based approach, will facilitate a potential implementation in clinical practice.
Detailed description
Despite our adequate medical care and financial support systems, the mental wellbeing and quality of life after cancer diagnosis and treatment is often poorly addressed in clinical settings. Previous research showed that Fear of Cancer Recurrence (FCR) is one of the most common psychological burdens faced by 39%-97% of cancer survivors. In this phase III randomized multicentre trial, patients will be allocated to either the iEFT group, iMMI group or wait-list control (WLC) group for a study trajectory of 6 weeks. 339 cancer survivors, between 6 months and 5 years since diagnosis, and who have completed their primary cancer treatment (i.e. surgery, radiation, and/or chemotherapy) will be enrolled and randomized 1:1:1 to one of the two intervention groups or the WLC group. Participants will complete evaluation questionnaires at baseline (T0), after 6 weeks (T1) and 12 weeks (T2) of intervention or waiting list, and 24 weeks (T3). A biomarker endpoint includes the measurement of chronic biologic stress in hair cortisol concentration. Therefore, optional hair collection may take place before (T0) and after the 6-week intervention (T1). Primary objective is to evaluate the feasibility and efficacy of iEFT and iMMI as an intervention strategy to reduce FCR in cancer survivors. The investigators hypothesize that an intervention with iEFT or iMMI will be superior compared to the WLC group at T1. Secondary objectives include the following:
Interventions
BEHAVIORALEmotional Freedom Techniques
Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
BEHAVIORALMindfulness Meditation
Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
Sponsors
Kom Op Tegen Kanker
az Glorieux
AZ Klina
AZ Vesalius
Imeldaziekenhuis
Jessa Hospital
University Hospital, Antwerp
Universitair Ziekenhuis Brussel
University Hospital, Ghent
Universitaire Ziekenhuizen KU Leuven
Vitaz
General Hospital Groeninge
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
This is a multi-site, randomized, three arm trial that will evaluate the efficacy of two distinct types of group interventions to target fear of cancer recurrence (FCR) in cancer survivors. The first intervention entails emotional freedom techniques (EFT). The other intervention is mindfulness meditation. The third group is the wait-list control group.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients should have reached a minimum age of 18 years at the time of enrolment * Patients should have a histologically confirmed diagnosis of a solid cancer or haematologic malignancy * Patients should have completed surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted drug therapy or a combination of these at least 2 months ago and no longer than 5 years ago at the time of enrolment * Patients should have an expected life expectancy of at least 5 years * Patients are disease-free at the time of enrolment, as defined by the absence of somatic disease activity parameters * Patients can be included in a stable phase of their immunotherapy (e.g. adjuvant use of checkpoint inhibitors for melanoma), hormonal therapy (e.g. for breast and prostate cancer), targeted drug therapy (e.g. trastuzumab and pertuzumab for breast cancer; stable dose of PARP inhibitors for ovarian cancer; retuximab for lymphoma), or a combination of these * Patients must suffer from high FCR based on the Cancer Worry Scale (cut-off ≥ 14) * Patients should be able to adequately communicate in Dutch * Patients should present with a sufficient mental and physical functional status (according to investigator's judgment and first baseline assessment) for completing the questionnaires and neuropsychological assessment * Patients under current treatment for a depression or anxiety disorder are allowed to enrol provided their depression or anxiety disorder is stable
Exclusion criteria
* Patients who received a treatment with palliative intent * Patients showing signs of mental deterioration * Patients suffering from organic brain syndrome (concussion without neurological symptoms and negative imaging is allowed) * Patients who are alcohol or drug dependent * Patients with another serious or chronic medical, neurologic or psychiatric condition that contributes to substantial physical or emotional disability that would detract from participating in either of the intervention programmes or from the measurement of intervention outcomes; a prior diagnosis of a depressive, anxiety or adjustment disorder is allowed * Patients who cannot commit to the intervention schedule; obstacles such as surgery or long-term hospitalisation, change of residence or work, … can have an emotional and practical impact which makes these patients not eligible for participation. * Patients who actively practice EFT or mindfulness(based) meditation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fear of Cancer Recurrence | 6 weeks (T1) | The primary endpoint will be reached after the first period of performing iEFT or iMMI during 6 weeks or be at the waiting list for 6 weeks (T1) where we will look at the efficacy of iEFT and iMMI to alleviate of Fear of Cancer Recurrence (FCR) based on the Fear of Cancer Recurrence Inventory (FCRI). FCRI has a minimum value of 0 and maximum value of 168, with a higher score pointing out to a worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Follow-up of Fear of Cancer Recurrence | T0 (baseline), T1 (6 weeks), T2 (12 weeks) and T3 (24 weeks) | Efficacy of iEFT and iMMI to reduce FCR (Fear of Cancer Recurrence Inventory; FCRI). FCRI has a minimum value of 0 and maximum value of 168, with a higher score pointing out to a worse outcome. |
| Psychological Distresss | T0 (baseline), T1 (6 weeks), T2 (12 weeks) and T3 (24 weeks) | Efficacy of iEFT and iMMI to reduce psychological distress (Distress Thermometer). Distress thermometer has a minimum value of 0 and maximum value of 10, with a higher score pointing out to a worse outcome. |
| Fear of Cancer Recurrence | T0 (baseline), T1 (6 weeks), T2 (12 weeks) and T3 (24 weeks) | Efficacy of iEFT and iMMI to enhance Quality of Life (EORTC QOL Cancer Survivorship Core Questionnaire (QLQ-SURV100), amended with items from the EORTC Core QOL questionnaire QLQ-C30). EORTC QLQ-SURV 100 has a minimum value of 100 and maximum value of 406, with a higher score pointing out to a better outcome. EORTC QLQ-C30 has a minimum value of 30 and maximum value of 126, with a higher score pointing out to a better outcome. |
| Number of participants continuing the intervention after T1 | T2 (12 weeks) and T3 (24 weeks) | To identify the continuous application of iEFT or iMMI, participants will need to answer the questionnaire about whether they cotinue the application of EFT or mindfulness meditation, and the frequency of application, post-intervention period. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biomarker endpoint | T0 (baseline), T1 (6 weeks), but this endpoint will be completed only when the primary objective would be positive at T1 | • Effect of iEFT and iMMI on chronic biological stress measure as hair cortisol concentration |
Countries
Belgium
Outcome results
None listed